Speaker illustration

Professor David Adams

Le Kremlin-Bicetre Cedex (France)

Phase 2 open-label extension (OLE) study of patisiran for the treatment of hereditary ATTR (hATTR) amyloidosis: 24-month safety and efficacy in subgroup of patients with cardiac involvement

Event: Heart Failure 2017 - 4th World Congress on Acute Heart Failure

Topic: Cardiomyopathies

Session: Rapid Fire 2 - Comorbodities


ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb